MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019
April 30 2019 - 9:00AM
MannKind Corporation (Nasdaq:MNKD) will release
its 2019 first quarter financial results on Tuesday, May 7, 2019
and its management will host a conference call to discuss the
financial results and other Company developments at 9:00 AM
(Eastern Time) on May 7, 2019.
Presenting from the Company will be its Chief
Executive Officer, Michael Castagna and Chief Financial Officer,
Steven Binder.
To participate in the live call by telephone,
please dial (800) 289-0438 or (323) 794-2423 and use the
participant passcode: 6329706. Those interested in listening to the
conference call live via the Internet may do so by visiting the
Company's website at http://www.mannkindcorp.com under News &
Events.
A telephone replay of the call will be
accessible for approximately 14 days following completion of the
call by dialing (844) 512-2921 or (412) 317-6671 and use the
participant passcode: 6329706. A replay will also be available on
MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company’s first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in
Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
Company Contact: Rose Alinaya SVP, Investor
Relations 818-661-5000 ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024